Advertisement

AIDS and Behavior

, Volume 22, Issue 5, pp 1671–1678 | Cite as

Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance

  • Habib O. Ramadhani
  • Charles Muiruri
  • Venance P. Maro
  • Balthazar Nyombi
  • Michael Omondi
  • Julian B. Mushi
  • Eileen S. Lirhunde
  • John A. Bartlett
Original Paper

Abstract

Patient-initiated repackaging of antiretroviral therapy (ART) refers to removal of ART medications from their original manufacturer’s containers, and putting them into alternative containers. This behavior may be triggered by stigma associated with HIV infection, and may impact patient outcomes. We assessed association between patient initiated repackaging of ART and failure to achieve viral suppression (FVS) in a sample of 450 HIV-infected adults (≥8 years) on first line ART for ≥6 months. FVS was defined as a plasma HIV RNA level ≥400 copies/mL. A total of 197 (43.7%) patients reported repackaging their ART medications. One hundred ninety-one patients (42.4%) failed to suppress and FVS was associated with medication repackaging [adjusted odds ratio (aOR), 2.2; 95% CI 1.4–3.3.] Adherence to ART was also associated with FVS (aOR; 0.4; 95% CI 0.2–0.6.). Benefits of retaining drugs in their original packaging along with adherence to ART should be emphasized to reduce the risk of FVS.

Keywords

HIV Repackaging of anti-retro-viral Virological suppression Stigma ART resistance mutations 

Notes

Acknowledgements

We thank the management of the 5 CTCs for invaluable assistance in conducting the study. We also thank study participants and other staff members for their assistance with this study. Moreover, we thank Godfrey Mushi, Gaudensia H. Lyimo and Rita P. Minja for conducting patient interviews and data collection.

Funding

This research was funded by the Duke Center For AIDS Research (CFAR), a National Institutes of Health-funded program (Grant Number P30 AI064518-06).

Compliance with Ethical Standards

Conflicts of interest

The authors have no conflicts of interest to declare.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Mutumba M, Bauermeister JA, Musiime V, Byaruhanga J, Francis K, Snow RC, et al. Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study. AIDS Patient Care STDS. 2015;29(2):86–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Martin F, Kiwanuka T, Kawuma R, Zalwango F, Seeley J. Tasks and strategies of self-management of living with antiretroviral therapy in Uganda. AIDS Patient Care STDS. 2013;27(12):697–706.CrossRefPubMedGoogle Scholar
  3. 3.
    Okoror TA, Falade CO, Olorunlana A, Walker EM, Okareh OT. Exploring the cultural context of HIV stigma on antiretroviral therapy adherence among people living with HIV/AIDS in southwest Nigeria. AIDS Patient Care STDS. 2013;27(1):55–64.CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Heneghan CJ, Glasziou P, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2006;1:Cd005025.Google Scholar
  6. 6.
    Zadbuke N, Shahi S, Gulecha B, Padalkar A, Thube M. Recent trends and future of pharmaceutical packaging technology. J Pharm Bioallied Sci. 2013;5(2):98–110.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Peitzmeier SM, Grosso A, Bowes A, Ceesay N, Baral SD. Associations of stigma with negative health outcomes for people living with HIV in the Gambia: implications for key populations. J Acquir Immune Defic Syndr. 1999;2015(68 Suppl 2):S146–53.Google Scholar
  8. 8.
    Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS ONE. 2014;9(5):e97353.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.CrossRefPubMedGoogle Scholar
  10. 10.
  11. 11.
    Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med. 2006;14(3):125–30.PubMedGoogle Scholar
  12. 12.
    Ndahimana J, Riedel DJ, Mwumvaneza M, Sebuhoro D, Uwimbabazi JC, Kubwimana M, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Health. 2016;21(7):928–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther. 2014;11(1):9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ngarina M, Kilewo C, Karlsson K, Aboud S, Karlsson A, Marrone G, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis. 2015;15:175.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clinical Infect Dis. 2007;44(1):128–34.CrossRefGoogle Scholar
  16. 16.
    Wilson IB, Bangsberg DR, Shen J, Simoni JM, Reynolds NR, Goggin K, et al. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64(5):448–54.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mbonye M, Seeley J, Ssembajja F, Birungi J, Jaffar S. Adherence to antiretroviral therapy in Jinja, Uganda: a six-year follow-up study. PLoS ONE. 2013;8(10):e78243.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS. 2007;21:S39–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, et al. The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr. 2004;36(1):622–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Y, Han Y, Xie J, Gu L, Li W, Wang H, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS. 2014;28(4):521–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Genberg BL, Hlavka Z, Konda KA, Maman S, Chariyalertsak S, Chingono A, et al. A comparison of HIV/AIDS-related stigma in four countries: negative attitudes and perceived acts of discrimination towards people living with HIV/AIDS. Soc Sci Med. 2009;68(12):2279–87.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tsai AC. Socioeconomic gradients in internalized stigma among 4,314 persons with HIV in sub-Saharan Africa. AIDS Behav. 2015;19(2):270–82.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tsai AC, Hatcher AM, Bukusi EA, Weke E, Lemus Hufstedler L, Dworkin SL, et al. A Livelihood Intervention to Reduce the Stigma of HIV in Rural Kenya: longitudinal qualitative study. AIDS Behav. 2016;21:248–60.CrossRefGoogle Scholar
  24. 24.
    Ramadhani HO, Muiruri C, Maro VP, Omondi M, Mushi JB, Lirhunde ES, et al. Association of knowledge on ART line of treatment, scarcity of treatment options and adherence. BMC Health Serv Res. 2016;16(1):265.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, et al. Association of first-line and second-line antiretroviral therapy adherence. Open Fforum Infect Dis. 2014;1(2):ofu079.CrossRefGoogle Scholar
  27. 27.
    Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 1999;2006(43 Suppl 1):S79–87.Google Scholar
  28. 28.
    Wu P, Johnson BA, Nachega JB, Wu B, Ordonez CE, Hare AQ, et al. The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa. Curr HIV Res. 2014;12(5):366–75.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    McMahon JH, Manoharan A, Wanke CA, Mammen S, Jose H, Malini T, et al. Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS Behav. 2013;17(6):2253–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Habib O. Ramadhani
    • 1
    • 2
  • Charles Muiruri
    • 3
  • Venance P. Maro
    • 1
    • 4
  • Balthazar Nyombi
    • 1
    • 2
  • Michael Omondi
    • 3
  • Julian B. Mushi
    • 5
  • Eileen S. Lirhunde
    • 6
  • John A. Bartlett
    • 3
    • 7
  1. 1.Kilimanjaro Christian Medical Centre, (KCMC)MoshiTanzania
  2. 2.Kilimanjaro Christian Medical University CollegeMoshiTanzania
  3. 3.Duke Global Health InstituteDurhamUSA
  4. 4.Mawenzi Regional HospitalMoshiTanzania
  5. 5.Kilema Designated District HospitalMoshiTanzania
  6. 6.Kibosho Designated District HospitalMoshiTanzania
  7. 7.Division of Infectious Diseases and International Health, Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations